STATEMENT OF NEED
Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine tumor of unknown origin that typically presents in older white and immunocompromised adults. An estimated 1,500 cases are diagnosed in the United States annually. The incidence of MCC has risen rapidly during the past few decades, which has been attributed in part to people living longer with increased sun exposure and weakened immune systems, a feature that suggests an infectious origin and warrants further research. Treatment standards are lacking and consequently clinical decision making is often empirical rather than evidence-based. The mortality rate for MCC presently exceeds that of melanoma. The overall 5-year survival rate ranges from 30% to 64%.
Medical oncologists, dermatologists, surgeons, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with MCC.
Upon completion of this activity, participants should be able to:
- Describe the pathophysiology of MCC and the scientific foundation for immune checkpoint inhibitors
- Apply emerging data on immune checkpoint inhibitors in treatment planning for patients with metastatic MCC
- Assess strategies to manage immune-related adverse events associated with immune checkpoint inhibitors
Learning objectives apply to all professions in the target audience.
Paul T. Nghiem MD, PhD
Professor & Head
University of Washington Dermatology
There is no fee to participate in or claim CME/CE credit for this activity.
Please note that the USF Health and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
Jointly Provided by
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and i3 Health. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS WITH COMMERCIAL INTERESTS
USF Health and i3 Health endorse the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
USF Health will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. USF Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
Paul T. Nghiem MD, PhD discloses that he has served as a consultant for Bristol-Myers Squibb, EMD Sorono, and Pfizer.
Planning Committee, USF Health OCPD staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.
Disclosures are on file at the University of South Florida, Office of Continuing Professional Development.
REQUIREMENTS FOR CREDIT
Participants must sign-in before the start of the activity to verify attendance. All participants are asked to complete a pretest and a posttest for outcomes assessment; a passing score is not required. At the conclusion of the activity participants must complete an evaluation, attesting to the time spent in this live activity, claiming credit. Certificates of Completion will be emailed to participants within two weeks of the activity.
UNAPPROVED USE DISCLOSURE
USF Health and i3 Health require CME/CE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an independent educational grant from Pfizer.